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Abstract
Background: CCL19 and CCL21, acting through CCR7, are termed homeostatic chemokines. Based on their role in
concerting immunological responses and their proposed involvement in tissue remodeling, we hypothesized that these
chemokines could play a pathogenic role in heart failure (HF).
Methodology/Principal Findings: Our main findings were: (i) Serum levels of CCL19 and particularly CCL21 were markedly
raised in patients with chronic HF (n=150) as compared with healthy controls (n=20). A CCL21 level above median was
independently associated with all-cause mortality. (ii) In patients with HF following acute myocardial infarction (MI; n=232),
high versus low CCL21 levels 1 month post-MI were associated with cardiovascular mortality, even after adjustment for
established risk factors. (iii). Explanted failing human LV tissue (n=29) had markedly increased expression of CCL21 as
compared with non-failing myocardium (n=5). (iv) Our studies in CCR7
2/2 mice showed improved survival and attenuated
increase in markers of myocardial dysfunction and wall stress in post-MI HF after 1 week, accompanied by increased
myocardial expression of markers of regulatory T cells. (v) Six weeks post-MI, there was an increase in markers of myocardial
dysfunction and wall stress in CCR7 deficient mice.
Conclusions/Significance: High serum levels of CCL21 are independently associated with mortality in chronic and acute
post-MI HF. Our findings in CCR7 deficient mice may suggest that CCL21 is not only a marker, but also a mediator of
myocardial failure. However, while short term inhibition of CCR7 may be beneficial following MI, a total lack of CCR7 during
long-term follow-up could be harmful.
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Introduction
Chronic heart failure (HF) is a disorder characterized by low-
grade immune activation and inflammation, as evident by elevated
circulating and myocardial levels of inflammatory cytokines and
chemokines, such as tumor necrosis factor (TNF)a, interleukin
(IL)-1b, monocyte chemoattractant protein (MCP)-1, and IL-8 [1].
Levels of these mediators may provide important prognostic
information, and several experimental studies have also suggested
a pathogenic role for inflammatory cytokines in HF [1,2].
However, the inflammatory response in HF remains to be
completely understood. Identification of the most important
mediators of the inflammatory pathways that could be involved
in the pathogenesis of HF as well as their mechanism of action are
issues that need further elucidation.
The chemokines CCL19 and CCL21, acting through their
common receptor, CCR7, are termed homeostatic due to their
role in immune surveillance and regulation of leukocyte movement
during homeostasis [3,4]. This chemokine system is primarily
thought to be involved in homing of naı ¨ve T cells and antigen-
presenting dendritic cells to lymph nodes. However, more recent
studies have revealed roles for CCR7 and its ligands in
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33038inflammation and T cell homing into non-lymphoid tissue as well
as in regulatory T cells (Tregs) trafficking, implying a more
complex role for CCR7 in immune responses [5,6]. Moreover,
recent studies suggest that CCR7 and its ligands are expressed in
non-lymphoid cells such as fibroblasts, vascular smooth muscle
cells (SMC), and endothelial cells, potentially being involved in
vascular inflammation, cell proliferation, and matrix remodeling
[7,8,9].
Based on their essential role in concerting immunological and
inflammatory responses as well as their newly discovered
involvement in tissue remodeling, we hypothesized that CCL19
and CCL21 may play a pathogenic role in HF. Here, we
elaborated this hypothesis by clinical studies in patients with
chronic HF and in patients with acute HF following myocardial
infarction (MI), as well as in studies of CCR7 deficient mice in an
animal model of post-MI HF.
Methods
Ethics
The clinical parts of this study were approved by the local
ethical committee (Regional ethics committee of Helse Sør-Øst;
Permit number S-05172) and conducted according to the ethical
guidelines outlined in the Declaration of Helsinki for use of human
tissue and subjects. Informed written consent was obtained from
all subjects. All animal experiments were carried out in accordance
with institutional guidelines, and conform to the Guide for the
Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23, revised
1996) and was approved by the Norwegian National Animal
Research Committee (permit of approval number STFDU2796).
Patients with chronic HF – cross-sectional analysis
Patients with stable HF (n=150) for .4 months in New York
Heart Association (NYHA) functional class II-IV, on optimal
cardiovascular treatment regimens, attending the Department of
Cardiology at Oslo University Hospital Rikshospitalet, were
consecutively included in the study (Table 1). Most of the patients
were evaluated by standard right- and left-sided cardiac
catheterization. The underlying cause of HF was classified as
ischemic heart disease (IHD; n=66, none with acute coronary
syndrome during the past 6 months) or dilated cardiomyopathy
(DCM; n=84) based on disease history and coronary angiogra-
phy. Control subjects were 20 sex- and age-matched apparently
healthy individuals based on disease history and clinical exami-
nation, but none of the controls underwent hemodynamic or
echocardiographic examination (Table 1). None of the controls
were taking any medication.
Patients with acute HF following MI – longitudinal
analyses
The design and main results of the OPtimal Trial In Myocardial
infarction with Angiotensin II Antagonist Losartan (OPTIMAAL)
have previously been reported in detail [10], Briefly, 5,477 patients
with acute MI complicated with HF during the acute phase were
randomly assigned and titrated to a target dose of losartan (50 mg
daily) or captopril (50 mg three times daily) as tolerated. Median
randomization time was 3 days after MI, and patients were
followed for a median of 2.7 years for mortality and morbidity
endpoints. The present study was a prospectively designed multi-
center sub-study of the main OPTIMAAL trial comprising 236
patients from six centers that was designed to analyze plasma/
serum levels of inflammatory mediators [11]. Except for the study
drugs (losartan versus captopril), there were no differences in
medications between the two treatment groups (Table 1). In both
sub-studies (i.e., cross-sectional and OPTIMAAL), blood sampling
was collected based on a strict protocols for blood sampling and
storage. Peripheral venous blood was drawn into pyrogen-free
blood collection tubes without any additives and allowed to clot
before centrifugation (1500 g for 10 minutes). All serum samples
Table 1. Characteristics of the study groups.
CTR Chronic HF Acute HF
(n=20) (n=150) Losartan (n=119) Captopril (n=117)
Age [years] 56 [43–69] 56 [58–82] 69 [69–89] 66 [51–88]
Male [%] 85 79 69 72
Etiology [IHD/DCM] 0/0 44/56 119 117
NYHA class [I/II/III/IV] 0/0/0/0 0/25/45/31 31/49/20/0 41/50/9/0
LV-EF [%] N/A 29 [9–81] 40 [20–60] 38 [15–60]
Nt-proBNP [pmol/L] 5 [1–13] 208 [1–4139] 1120 [152–2981] 1293 [176–3622]
Creatinine [mmol/L] 84 [61–94] 87 [44–459] 89 [55–209] 89 [61–190]
Medication [%]
Medication [%]:
ACE inhibitor 0 71 0 100
Angiotensin II receptor blocker 0 20 100 0
b-blocker 0 80 78 72
Diuretics 0 71 71 75
Warfarin 0 42 20 17
HMG-CoA reductase inhibitors 0 43 61 64
Data are median and range or number or percentage of subjects. Controls were healthy age- and sex-matched subjects. ACE, angiotensin converting enzyme; CAD,
coronary artery disease; DCM, dilated cardiomyopathy; HMG-CoA, hydroxymethylglutaryl coenzyme A; IHD; ischemic heart disease; LV-EF, left ventricular ejection
fraction; N/A, not available.
doi:10.1371/journal.pone.0033038.t001
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patients with significant concomitant disease such as infection,
malignancy, or autoimmune disorder were not included and none
were receiving immunosuppressive drugs.
Tissue sampling from human myocardium
Tissue samples from human failing myocardium were removed
from still-beating hearts immediately on explantation from 29
patients with end-stage HF (NYHA class III or IV; left ventricular
(LV) ejection fraction [LV-EF] ,35%; 21 DCM, 10 IHD; age
4763 years) undergoing cardiac transplantation. Control human
LV tissue was obtained from subjects whose hearts were rejected as
cardiac donors for surgical reasons (n=5). The cause of death of
donors was cerebrovascular accident, and none had a history of
heart disease. The hearts from these subjects had been kept on ice
for 1 to 4 hours before tissue sampling. In nine patients with
advanced HF (NYHA class IV; 8 male, 1 female; age 2965 years),
LV tissue was sampled at the time of implantation and at the time of
removal (heart transplantation) of a continuous-flow LV assist
device (LVAD; VentrAssist, Ventracor Ltd, Chatswood, Australia).
Average time on LVAD was 861.7 months. In both failing and
non-failing myocardium, LV tissue samples were snap-frozen in
liquid nitrogen, and stored at 280uC until use. None of the patients
(failing and control myocardium) had significant concomitant
disease such as infection, malignancy, or autoimmune disorder.
Miscellaneous
Serum levels of CCL19 and CCL21 were measured by enzyme
immunoassays provided from R&D Systems (Minneapolis, MN).
Serum levels of N-terminal pro-brain natriuretic peptide (Nt-
proBNP) and C-reactive protein (CRP) were determined as
previously reported [11].
Mouse model of experimental post-MI HF
C57BL/6 mice were purchased from Møllergaard (Møllergaard,
Denmark). CCR7
2/2 mice were backcrossed for at least 8
generations onto the C57BL/6 background [12], and bred at the
Institute for Experimental Medical Research, Oslo University
Hospital Ulleva ˚l. CCR7
2/2 and wild type (Wt) mice were
characterized after ligation of the left coronary artery (MI) or sham
operation. MI was induced in 8 week old mice as described [13].
Sham-operated animals underwent the same procedure except
ligation of the artery. Seven days or six weeks after surgery, the
animals were anesthetized and ventilated before echocardiography
was carried out, as described elsewhere [13]. Echocardiography was
carried out using a VEVO 2100 (Visualsonics, Toronto, Canada)
before the animals were sacrificed. Echocardiographic examina-
tions were performed under standardized conditions with the
animals in the supine position, spontaneously breathing 1.5%
isoflurane and 98.5% O2 on a mask. Echocardiographic data were
analyzed off-line using VEVO 2100 1.1.0 software from Visualso-
nics. Three representative cycleswereanalyzed and averaged. Two-
dimensional (2D) images of the LV were obtained both in long and
short axes. Short axis recordings were obtained at the level of the
papillary muscle. M-mode tracings were recorded in the long axis at
the level of the papillary muscles and the aortic valves, with 2D
guidance. LV wall thickness and cavity dimensions were measured
through the largest diameter of the ventricle both in systole and
diastole. LV fractional shortening (LVFS) in percent, was calculated
using the following formula: LVFS=(LVDd2LVDs)/LVDd6100
where LVDd is LV diameter in diastole, and LVDs is LV diameter
in systole. Doppler recordings were obtained in the left parasternal
long axis position. Pulsed wave Doppler was used for measuring
flowvelocities inthe leftventricularoutflowtract (LVOT) and inthe
mitral annulus. Cardiac output (CO) was calculated in LVOT using
the following equation: CO=LVOT VTI6p6(diameter/
2)
26heart rate where VTI is the velocity time integral and diameter
is measured in LVOT. The animals were subsequently euthanized
and their hearts were removed and blotted dry. The non-infarcted
LV, infarcted area, right ventricular free wall, and lungs were
weighed and normalized to tibia length. Based on previous findings
[13], only mice with an infarction circumference .40% of total LV
circumference, lung weights .133% of the average of the sham
group, and a left atrium diameter .20 mm measured by 2D
echocardiography were considered to have HF and were included
in the post-MI HF group.
Quantitative Real-Time RT-PCR
Total RNA from mouse and human myocardium was extracted
using TRIzol (Invitrogen, San Diego, CA), DNase treated, cleaned
up using RNeasy Mini Columns (Qiagen, Hilden, Germany), and
stored at 280uC. cDNA was synthesized from 1 mg RNA using
High Capacity cDNA Archive Kit (Applied Biosystems, Foster
City, CA). Quantification of gene expression was performed using
the ABI Prism 7500 (Applied Biosystems), 5 ng cDNA, Power
SYBR Green Master Mix (Applied Biosystems), and sequence-
specific PCR primers were designed using the Primer Express
software, version 3.0 (Applied Biosystems). Primer sequences can
be provided on request. Gene expression of the housekeeping gene
GAPDH was used for normalization.
Immunohistochemistry
Formalin fixed and paraffin-embedded mouse LV was immu-
nostained with anti-CCL21 (diluted 1:40 in PBS; R&D Systems),
and anti-CD45 (diluted 1:100 in PBS; Millipore, Bedford, MA).
For forkhead box P3 (foxP3) analysis, acetone-fixed cryosections
were stained with anti-foxP3 antibody (diluted 1:100 in 16PBS;
eBiosciences, Cambridge, UK). Omission of the primary antibody
served as negative control. The immunoreactivities were amplified
by the avidin-biotin-peroxidase system (Vectastain Elite kit, Vector
Laboratories) according to the manufacturers’ instructions.
Diaminobenzidine was used as the chromogen. The sections were
counterstained with hematoxylin or eosin (foxP3). For the
quantification of foxP3-positive cells, we randomly counted and
averaged five fields (406magnification) in the area bordering the
myocardial infarction.
Masson trichrome staining of formalin-fixed and paraffin-
embedded mouse hearts were performed using the Trichrome




was used a priori. For investigating treatment effects, repeated-
measures ANOVA was performed a priori on log transformed values
if necessary as evaluated by the Kolmogorov-Smirnov test, with
time and treatment as fixed factors and subject as random. For
comparisons of 2 groups of individuals, the Mann-Whitney U test
was used. Coefficients of correlation were calculated by the
Spearman rank test. Receiver-operating characteristics (ROC)
curve were generated to evaluate the accuracy of each marker for
prediction of all-cause and cardiovascular (CV) mortality. Kaplan-
Meier analysis with log-rank test was performed to compare the
number of events in different groups (comparisons pooled over
strata). Cox proportional hazard analysis was performed to estimate
hazard ratios using a forced method adjustingfor age, hypertension,
diabetes type 2, etiology, creatinine, CRP and Nt-proBNP. CCL21
was dichotomized (cross sectional study) or divided into tertiles with
CCL21 in Heart Failure
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time for all-cause mortality was calculated from time of inclusion to
death from any cause. P values are two-sided and considered
significant when ,0.05. All analyses were performed with SPSS for
Windows version 15.0 (SPSS, Chicago, IL).
Results
Serum levels of CCL19 and CCL21 are elevated and
CCL21 levels predict mortality in patients with chronic HF
As shown in Figure 1A–B, patients with chronic HF (n=150) had
significantly raised serum levels of CCL19 and CCL21 compared to
healthy controls (n=20). While CCL19 was not significantly
different according to NYHA class, particularly high CCL21
concentrations were found in those with the most severe HF
(Figure 1A–B). Moreover, CCL21, but not CCL19 was correlated to
poor cardiac function as estimated by cardiac index (r=20.35,
p,0.001) and neurohormonal activation by means of Nt-proBNP
(r=0.39, p,0.001). Furthermore, patients with IHD (n=66) had
markedly elevated CCL21 compared to patients with DCM (n=84)
(747666 pg/mL versus 494646 pg/mL, p=0.001), and notably,
an opposite pattern was seen for CCL19 with the highest levels in
DCM (129610 pg/mL versus 154697 pg/mL, p=0.05). Impor-
tantly, however, both etiological sub-groups had significantly raised
Figure 1. Serum levels of CCL19 and CCL21 are elevated and CCL21 levels predict mortality in patients with chronic heart failure
(HF). The top panels show serum levels of CCL19 (A) and CCL21 (B) in patients with chronic HF (n=150; NYHA class II/III/IV, n=40, 71, and 39,
respectively) and in 20 sex- and age-matched healthy controls, and (C) shows ROC curve analysis for the predictive value of CCL19, CCL21, and NT-
proBNP for all-cause mortality during 24 months follow-up. AUC and 95% CI are given. The bottom panels show (D) Kaplan–Meier curves
demonstrating the association between dichotomized serum levels of CCL19, CCL21, and NT-proBNP and incidence of all-cause mortality during 24
months follow-up, and (E) Cox-regression models adjusting for age and creatinine levels (Model 1), additional adjustment for LDL cholesterol,
hypertension, diabetes type 2, and etiology (Model 2), and additional adjustment for CRP and Nt-proBNP (Model 3). Data are mean6SEM. *p,0.05,
**p,0.01, and ***p,0.001 versus controls; {{p,0.01 versus NYHA class II and III.
doi:10.1371/journal.pone.0033038.g001
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(data not shown). Levels of CCL21, but not CCL19, were
significantly correlated with age in the HF patients (r=0.37;
p,0.001). Importantly, however, the difference between HF
patients and controls was statistically significant also after adjusting
for age (p,0.001 for both CCL19 and CCL21). In contrast to the
interaction with age (CCL21), we found no interaction between
gender and serum levels of CCL19 and CCL21 (data not shown).
During a mean follow-up of 24 (612 [SD]) months, 32 patients
died. ROC curves showed comparable area under curve (AUC)
for CCL21 and NT-proBNP, with lower levels for CCL19
(Figure 1C). A combined ROC curve for CCL19 and CCL21
showed no discriminatory properties (AUC [0.56, 95% confiden-
tial interval [CI] [0.46–0.66]) as compared with ROC curves for
CCL21 alone (Figure 1C).
As depicted in Figure 1D, CCL21 levels above median levels, but
not CCL19 levels, were closely associated with all-cause mortality
in this population. Similar to CCL21, high levels of NT-proBNP
(.median levels) were associated with significant increased all-
cause mortality during follow-up (Figure 1D). When comparing
high versus low CCL21 concentrations in the total patient
population, correcting for age and creatinine levels, the hazard
ratio (HR) was 2.84 (1.39–5.82), p=0.004 (Figure 1E, model 1).
After additional adjustment for LDL cholesterol, hypertension,
diabetes type 2, etiology (Figure 1E, model 2), and CRP and Nt-
proBNP (Figure 1E, model 3), this relationship remained signifi-
cant. Also, the cox-regression indicated that CCL21 alone was the
only predictor when analyzed together with CCL19 alone and
with the interaction term (data not shown).
Serum levels of CCL21 predict mortality in patients with
acute post-MI HF –results from the OPTIMAAL trial
At baseline, i.e., randomization time, significantly elevated levels
of CCL21, but not of CCL19, were found in patients with NYHA
class III as compared with those in NYHA class I/II (Figure 2A),
and this difference persisted throughout the study period
(Figure 2B). Moreover, at all time points, CCL21, but not
CCL19, were significantly correlated with plasma levels of Nt-
proBNP (Figure 2C). During an average follow-up of 27 months,
there was no difference between the captopril and the losartan
group in relation to total (n=32) and CV (n=26) mortality or in
Figure 2. Serum levels of CCL21 predict mortality in patients with acute post-myocardial infarction (MI) heart failure (HF). Panels A
and B show serum levels of CCL19 and CCL21 at baseline (BL; randomization time) (A) and in relation to NYHA functional class during follow-up (B)i n
a total of 236 HF patients. Data are mean6SEM. *p,0.05 and **p,0.01 versus NYHA class I/II. Panel C shows the correlation between serum levels of
CCL21 and Nt-proBNP at baseline and at different time points during follow-up. Yr, year. Panel D shows ROC curve analysis for the predictive value of
CCL19, CCL21, and NT-proBNP for all-cause mortality (n=32) during 2.7 years follow-up at baseline and 1 months. AUC and 95% CI are given. Panel E
shows Kaplan–Meier curves demonstrating the association between tertiles of serum CCL21 levels at 1 month and incidence of all-cause and CV
mortality during 24 months follow-up. Panel F shows Cox-regression models for the tertile 3 of CCL21 versus tertile 1 and 2 combined either
unadjusted (Model 1) or adjusted for age, creatinine levels, LDL cholesterol, hypertension, diabetes type 2, CRP and Nt-proBNP (Model 2).
doi:10.1371/journal.pone.0033038.g002
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33038Figure 3. Myocardial CCL21 expression is increased in clinical and experimental heart failure. Gene expression of CCL21 in left
ventricular tissue from (A) controls (donor hearts rejected for transplantation; n=5) and explanted failing hearts (n=29) and (B) heart failure patients
(n=9) during the implantation (preLVAD) and removal (postLVAD) of a continuous-flow LV assist device. The middle panels show gene expression of
CCL21 (C) and CCR7 (D) in non-ischemic left ventricular tissue (LV) and infarcted area (MI) in mice 3, 7 or 21 days (d) after MI (n=6–8) or sham
operation (n=6). mRNA levels were quantified by real-time RT-PCR and are presented relative to the gene expression of GAPDH. Data are
mean6SEM. *p,0.05, **p,0.01 and ***p,0.001 vs. controls/sham. The bottom panels show immunohistochemical staining (magnification6100) of
CCL21 in Heart Failure
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ROC analysis showed that CCL21 levels, but not CCL19 levels,
after 1 month, but not at baseline, were associated with total
mortality and in particular CV death, with an AUC exceeding that
of Nt-proBNP (Figure 2D). Kaplan-Meier plot showed a higher
total mortality and CV death in patients in the highest CCL21
tertile as compared with the other patients (Figure 2E). When
comparing high versus low CCL21 concentrations in the total
patient population (highest versus two lower tertiles), the
unadjusted HR was 4.33 (1.63–11.54); p=0.002) and 4.36
(1.48–12.68); p=0.007), total and CV death, respectively
(Figure 2F, model 1). This relationship remained significant for
CV death, but not for total mortality also after adjustment for age,
creatinine levels, LDL cholesterol, hypertension, diabetes type 2,
CRP and Nt-proBNP (Figure 2F, model 2).
Myocardial CCL21 expression is increased in clinical and
experimental HF
As shown in Figure 3A, the failing LV in 29 patients with
advanced HF (NYHA class IV) had markedly increased expression
of CCL21, but not of CCR7 and CCL19 (data not shown), as
compared with the non-failing LV (n=5) as assessed by real-time
RT-PCR. Average Ct values for CCL21, CCR7, CCL19 and
GAPDH were 27.3, 30.2, 30.7 and 18.8, respectively. In 9 of the
patients, the improvement in hemodynamic and neurohormonal
parameters that was seen during continuous-flow LV assist device
(median follow-up time 8 months, range 1–18 months), was
accompanied by a marked decrease in CCL21 mRNA levels, and
this decrease was seen in 8 of the 9 patients (Figure 3B). Finally, we
examined the myocardial expression of CCL21 and CCR7 in
post-MI HF mice. In this experimental model of HF we found a
significant myocardial up-regulation of CCL21 and CCR7
following MI. While persistently raised CCR7 levels were seen
throughout the observation period (i.e., 21 days), CCL21 showed a
more gradual rise with particular enhanced expression after 21
days (Figure 3C–D). Immunohistochemistry showed specific
myocardial immunostaining of CCL21 in sham-operated and in
particular in post-MI HF mice, with particularly strong immuno-
staining in endothelial cells (Figure 3E–G). Unfortunately, we were
not able to obtain reliable immunostainings for CCR7.
Improved survival in post-MI HF in CCR7
2/2 mice
Our data so far may suggest activation of CCR7 in experimental
and clinical HF. To elucidate potential functional consequences of
these findings, we studied the effect of targeted disruption of CCR7
in a model of post-MI HF. As depicted in Kaplan-Meier survival
curves, CCR7
2/2 mice exhibited significantly higher survival rates
than Wt mice during an 6 weeks follow-up after induction of post-
MI HF (Figure 4). A total of 73 Wt and 51 CCR7
2/2 mice were
included. During follow-up 44 (60.3%) Wt and 19 (37.3%)CCR7
2/2
mice died, reflecting improved survival in CCR7 deficient mice
during the first week of follow-up (Figure 4).
Expression of markers of myocardial function and fibrosis
in post-MI HF in CCR7
2/2 mice
As shown in Figure 5A–D, the improved survival rate during the
first week in CCR7
2/2 mice was accompanied by an attenuated
increase in the expression of ANP, BNP, a-SKA, and b-MHC/a-
MHC ratio CCR7
2/2 as compared with Wt mice following MI,
potentially suggesting attenuated wall stress and improved
myocardial function in CCR7 deficient mice. Somewhat surpris-
ingly, an opposite pattern was seen 6 weeks following MI with
increased ANP, BNP and b-MHC/a-MHC ratio expression in
CCR7
2/2 mice as compared with Wt mice (Figure 5A–D). As
assessed by echocardiography, the differences between CCR7
2/2
and Wt mice were modest and non-significant after 1 week
(Table 2). However, the increase in myocardial expression of ANP,
BNP and b-MHC/a-MHC ratio in CCR7
2/2 mice 6 weeks after
MI, was accompanied by an increase in LV diameter and a
decrease in posterior LV wall thickness in diastole in these mice as
compared with Wt mice, indicating increased LV dilation in
CCR7 deficient mice at this time-point (Table 3). On the other
hand, the degree of fibrosis as assessed by Masson trichrome
staining in non-ischemic LV after 6 weeks showed no difference
between sham-operated and post-MI HF mice, suggesting no or
only minor differences in myocardial remodeling (Figure 5E–F).
Increased myocardial expression of Foxp3, IL-10 and
transforming growth factor (TGF)-b1 during post-MI HF
in CCR7 deficient mice
As shown in Figure 6A, mRNA levels of CD3, a pan-T cell
marker, were significantly increased in both sham-operated and
post-MI HF CCR7
2/2 mice after 1 week. CCR7 has been
implicated in the regulation of Tregs trafficking [6], and mRNA
levels of Foxp3, a sensitive marker for Tregs, exhibited markedly
different pattern in the two types of mice. Whereas Foxp3
expression was significantly decreased in post-MI HF as compared
with sham operated Wt mice after 1 week, the myocardial
expression of Foxp3 was markedly enhanced in CCR7
2/2 mice
with no difference between sham operated and HF mice,
potentially reflecting a phenotypic characteristic of these mice
(Figure 6B). Also, immunohistochemistry showed strong Foxp3
immunostaining within the LV of post-MI CCR7
2/2 mice as
compared with LV from post-MI Wt mice (Figure 6C–F). IL-10 and
TGF-b have been related to the function of Tregs [14], and the
increased expression of Foxp3 in CCR7
2/2 mice was accompa-
nied by a marked increase in IL-10 in post-MI HF, but not of
CCL21 in LV from sham operated mouse (E) and mouse 1 week after MI (F) and a negative control image (G; omission of primary antibody). Arrows
indicate CCL21-positive cells.
doi:10.1371/journal.pone.0033038.g003
Figure 4. Improved survival in CCR7 deficient mice after
myocardial infarction. Kaplan-Meier curve demonstrating increased
survival in CCR7
2/2 mice as compared to wild type mice after
myocardial infarction. Differences in survival were tested with the log-
rank test.
doi:10.1371/journal.pone.0033038.g004
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pattern was seen after 6 weeks in the post-MI model with increased
expression of CD3, Foxp3 and IL-10 in CCR7
2/2 as compared
with Wt mice (Figure 6A, B and G). However, while there was no
increase in TGF-b1 in CCR7
2/2 post-MI HF mice after 1 week,
the myocardial expression of TGF-b1 in these mice after 6 weeks
was markedly increased (Figure 6H). In contrast to the difference in
Tregs related markers, mRNA levels of inflammatory cytokines
(i.e., TNFa and MCP-1; Figure 7A–B) and CD45 immunostaining
as a marker of leukocyte infiltration (Figure 7C–D), showed no
differences between the two genotypes.
Discussion
CCR7 and its ligands have previously been related to various
inflammatory disorders such as rheumatoid arthritis, inflammatory
bowel disease, and atherosclerosis [8,15,16]. Our data suggests
that this chemokine system also could be involved in the
development of HF. For the CCR7 ligand CCL21, markedly
enhanced expression was found both systemically and within the
failing myocardium in human HF. Moreover, high serum levels of
CCL21 were independently associated with increased mortality in
both chronic HF and acute HF following MI. Our studies in
Figure 5. The myocardial expression of markers of myocardial hypertrophy and wall stress in CCR7
2/2 and Wt mice one and six
weeks post-myocardial infarction (MI). The panels show the gene expression of ANP (A), BNP (B), b-myosin heavy chain (MHC) to aMHC ratio
(C), and a-skeletal actin (aSKA; D) in the left ventricle one and six weeks following sham operation or myocardial infarction (MI) in Wt (1w: n=7+8; 6w:
n=5+7) and CCR7 deficient (1w: n=6+9; 6w: n=8+9) mice (numbers denote sham operation and post-MI HF, respectively). mRNA levels were
quantified by real-time RT-PCR and are presented relative to the gene expression of GAPDH. Data are mean6SEM. *p,0.05, **p,0.01 and
***p,0.001 versus sham operation in the same genotype. {p,0.05, {{p,0.01 and {{{p,0.001 versus Wt post-MI HF. Lower panels are
representative images of Masson trichrome stained non-ischemic LV (magnification 106) from Wt mouse (E) and CCR7
2/2 mouse (F) six weeks after
MI.
doi:10.1371/journal.pone.0033038.g005
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2/2 mice showed improved survival and attenuated
increase in markers of myocardial dysfunction and wall stress in
post-MI HF after 1 week. However, an opposite pattern was seen
after 6 weeks with increased ANP, BNP and b-MHC/a-MHC
expression in post-MI CCR7
2/2 mice as compared with Wt mice.
Although there was no increased mortality in CCR7
2/2 mice
after the first week, these latter findings may suggest impaired
myocardial function during long-term follow-up in CCR7
deficient mice. Thus, while short-term inhibition of CCR7
signaling may be beneficial following MI, a total lack of CCR7
during long-term follow-up could be harmful, illustrating the fine
balance between adaptive and maladaptive effects of inflammatory
and anti-inflammatory mediators in post-MI remodeling and
development of HF. Moreover, while enhanced expression of
CCL21 as in clinical HF may be harmful, a total and persistent lack
of its receptor, CCR7, may also have harmful effects on
myocardial remodeling.
A wide range of inflammatory markers are elevated during HF
such as TNFa, IL-6, IL-1, and various inflammatory chemokines
[1]. The present study, however, is the first report of elevated
serum levels of homeostatic chemokines in HF patients. We
previously showed increased levels of CCL19 and CCL21 in
coronary artery disease [8], and it may be argued that the raised
levels of these mediators in HF merely reflect that several of these
patients also have accompanying atherosclerosis. However,
although patients with ischemic etiology had particularly elevated
CCL21 levels, also patients with DCM had raised serum CCL21
levels compared with controls. Moreover, the ability of serum
levels of CCL21 to predict survival in both chronic HF and in
acute post-MI HF, even after adjustment for several confounders
such as age, hypertension, GFR, CRP, and Nt-proBNP as well as
the etiology of HF, may further suggest the involvement of CCR7
activation in the progression of HF. The significant decrease in the
myocardial expression of CCL21 following hemodynamic and
neurohormonal improvement during continuous-flow LV assist
device treatment in advanced HF, gives additional support to a
link between high CCL21 expression and impaired myocardial
performance.
In contrast to CCL21, CCL19 showed no association with
mortality in HF patients and no myocardial increase in advanced
HF. The different association between CCL19 and CCL21 and
parameters of HF may have several not-mutually exclusive
explanations. First, while CCL19 is produced by several types of
cells such as T cells, monocytes and macrophages, CCL21 seems
primarily to be produced by stromal cells [3]. It is possible that the
ability of CCL21 to predict mortality may reflect its regulation in
stromal-related cells within the myocardium. Second, CCL21 has
been found to induce more potent inflammatory effects in
macrophages than CCL19 [8], potentially implicating a more
important role in certain inflammatory disorders. Finally, although
both chemokines are acting through CCR7, they could still
mediate, at least in some degree, different effects. In fact, we have
data showing that CCL19 and CCL21 differently affect both
macrophages and vascular smooth muscle cells (Aukrust P,
Yndestad A, unpublished data).
Decreased Tregs have been related to various autoimmune
diseases, and appear to be involved in the pathogenesis of some
CV disorders (e.g., atherosclerosis and heart allograft rejection)
[14,17,18]. Recently, transfer of Tregs into angiotensin II-infused
Table 2. Animal characteristics and echocardiographic
measurements in CCR7 deficient and wild-type mice 1 week






(n=7–8) (n=7–8) (n=14) (n=14)
Characteristics
BW, g 21.861.1 23.261.1 20.661.1 20.861.0
TL, mm 16.160.2 16.160.1 16.160.1 15.960.1
Heart rate, bpm 333616 406635 400626 390615
LVW, mg 76627 4 619 3 61* 11061*
INFW, mg - - 3.160.5 3.260.3
RVW, mg 19622 0 631 9 60.3 2760.2
LW, mg 145621 3 7 632 1 4 619* 274616*
Echo-MM
Inf. circ., mm - - 10.860.7 11.560.7
LVDd, mm 3.760.2 3.360.1{ 4.860.1* 5.160.1*
PWd, mm 0.960.04 0.960.03 0.860.04* 0.860.04
LVFS, % 24622 2 621 2 61* 1161*
Sham, 9–11 week old sham-operated group; MI, 9–11 week old myocardial
infarction group; WT, wild-type mice; CCR7
2/2, CCR7 knock-out mice; BW, body
weight; TL, tibia- length; bpm, beats per minute; LVW, left ventricular weight;
INFW, infarction weight; RVW, right ventricular weight; LW, lung weight; Echo-
MM, M-mode echocardiography; Inf. circ, infarct circumference; LVDd, left
ventricular diameter in diastole; PWd, posterior wall thickness in diastole; LVFS,
left ventricular fractional shortening;
*p,0.05 vs sham in respective genotype
group. Values are means6SEM.
doi:10.1371/journal.pone.0033038.t002
Table 3. Animal characteristics and echocardiographic
measurements in CCR7 deficient and wild-type mice 6 weeks






(n=7–8) (n=7–8) (n=7–8) (n=10–11)
Characteristics
BW, g 28.360.6 27.361.0 30.360.6 28.960.8
TL, mm 16.960.2 17.260.2 17.160.1 17.460.1
Heart rate, bpm 425617 409621 428621 499617
LVW, mg 90629 8 641 2 4 66* 13965*
INFW, mg - - 42634 5 64
RVW, mg 24612 5 613 2 623 5 62
LW, mg 148631 191618 197612* 243627*
Echo-2D
LV circ/Inf. circ, % - - 51625 7 63
Echo-MM
LVDd, mm 4.160.2 4.560.09 6.460.2* 7.060.02*{
PWd, mm 0.8160.06 0.8060.03 0.8660.05* 0.7160.04{
LVFS, % 22622 0 619 62* 861*
EF, % 43644 1 622 0 63* 2163*
MI, myocardial infarction; WT, wild-type mice; CCR7
2/2, CCR7 knock-out mice;
BW, body weight; TL, tibia- length; bpm, beats per minute; LVW, left ventricular
weight; INFW, infarction weight; RVW, right ventricular weight; LW, lung weight;
Echo-2D, two-dimensional echocardiography; LV circ/Inf. circ, left ventricular
circumference/infarct circumference; Echo-MM, M-mode echocardiography;
LVDd, left ventricular diameter in diastole; PWd, posterior wall thickness in
diastole; LVFS, left ventricular fractional shortening; EF, ejection fraction;
*p,0.05 vs sham in respective genotype group and
{p,0.05 vs Wt in same
group. Values are means6SEM.
doi:10.1371/journal.pone.0033038.t003
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despite sustained hypertension [19]. Based on these and the
present data, it is tempting to hypothesize that Tregs also could be
involved in the pathogenesis of HF. During post-MI HF there was
a significant decrease in the myocardial Foxp3 expression in Wt
mice, as a marker of Tregs. In contrast, the myocardial expression
of Foxp3 was markedly enhanced in CCR7
2/2 mice in both
sham-operated and HF mice, potentially representing a pheno-
typic characteristic of these mice. It has previously been shown
that CCR7 deficiency promotes the accumulation of Treg subsets
in inflamed sites, accompanied by an enhanced suppression of the
inflammatory reaction, suggesting a role for CCR7 in Tregs
trafficking [5]. Following MI, CCR7
2/2 but not Wt mice showed
marked up-regulation of myocardial IL-10, a Treg-related
cytokine that has been shown to inhibit post-MI LV remodeling
[20]. However, a similar pattern was also seen after 6 weeks when
the myocardium in CCR7
2/2 mice showed increased levels of
markers of myocardial dysfunction and wall stress. The reason for
this pattern is not clear. However, it is possible that while a short-
term increase in Tregs and IL-10 following MI, when Wt mice
showed decreased Foxp3 expression, is adaptive, persistently
increased levels may be maladaptive. In fact, the disappointing
results of IL-10 therapy in inflammatory disorders may reflect that
long-term administration may induce maladaptive responses,
including enhanced B cell activation [21]. However, further
studies are needed to elucidate the regulation and potential role of
Tregs during myocardial remodeling.
The present study has some limitations such as the inclusion of
relatively few patients and in particular, the number of controls
was low. Also, the lack of IHC from human heart, the lack of IHC
on CCR7, and the lack of data on serum levels of CCL19 and
CCL21 in the mice model are other limitations. Moreover, the
changes in echocardiographic variables were rather modest.
However, mRNA markers of myocardial remodelling showed
profound alterations, suggesting that these may be more robust
markers of myocardial dysfunction in this model. The association
between the attenuated up-regulation of these markers and
improved survival further support such a notion. Finally, systemic
deletion of CCR7 has some confounders, and future studies should
also examine the effect of cardiac-restricted deficiency of CCR7.
Nonetheless, our studies, combining experiments in clinical and
experimental HF, suggest a role for CCL21/CCR7 interactions in
the pathogenesis of HF.
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Figure 7. Myocardial gene expression of inflammatory markers in wild type and CCR7 deficient mice during post-MI HF. Left sided
panels show gene expression of monocyte chemoattractant protein (MCP)-1 (A) and tumor necrosis factor (TNF)a (B) in the LV one and six weeks
following sham operation or MI in Wt (1w: n=7+8; 6w: n=5+7) and CCR7 deficient (1w: n=6+9; 6w: n=8+9) mice (numbers denote sham operation
and post-MI HF, respectively). mRNA levels were quantified by real-time RT-PCR and are presented relative to the gene expression of GAPDH. Data are
mean6SEM. *p,0.05, and ***p,0.001 versus sham operation in the same genotype. Right sided panels show representative images of
immunohistochemical staining of CD45 as a pan-leukocyte marker (magnification 406) in LV tissue from a Wt mouse (C) and a CCR7
2/2 mouse (D)
one week post-MI. Arrows indicate CD45-positive cells.
doi:10.1371/journal.pone.0033038.g007
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